Meyka Pro banner
DURECT Corporation

DURECT Corporation Fundamental Analysis

DRRXNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$1.91
$0.02(1.04%)
U.S. Market is Open · 15:58

DURECT Corporation Fundamental Analysis

DURECT Corporation (DRRX) shows weak financial fundamentals with a PE ratio of -9.41, profit margin of -8.46%, and ROE of -1.40%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position10.97%
PEG Ratio-0.05

Areas of Concern

ROE-1.40%
Operating Margin-9.04%
Current Ratio0.98
We analyze DRRX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -942.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-942.7/100

We analyze DRRX's fundamental strength across five key dimensions:

Efficiency Score

Weak

DRRX struggles to generate sufficient returns from assets.

ROA > 10%
-52.05%

Valuation Score

Excellent

DRRX trades at attractive valuation levels.

PE < 25
-9.41
PEG Ratio < 2
-0.05

Growth Score

Weak

DRRX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

DRRX shows balanced financial health with some risks.

Debt/Equity < 1
0.44
Current Ratio > 1
0.98

Profitability Score

Weak

DRRX struggles to sustain strong margins.

ROE > 15%
-139.90%
Net Margin ≥ 15%
-8.46%
Positive Free Cash Flow
No

Key Financial Metrics

Is DRRX Expensive or Cheap?

P/E Ratio

DRRX trades at -9.41 times earnings. This suggests potential undervaluation.

-9.41

PEG Ratio

When adjusting for growth, DRRX's PEG of -0.05 indicates potential undervaluation.

-0.05

Price to Book

The market values DURECT Corporation at 15.06 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

15.06

EV/EBITDA

Enterprise value stands at -10.14 times EBITDA. This is generally considered low.

-10.14

How Well Does DRRX Make Money?

Net Profit Margin

For every $100 in sales, DURECT Corporation keeps $-8.46 as profit after all expenses.

-8.46%

Operating Margin

Core operations generate -9.04 in profit for every $100 in revenue, before interest and taxes.

-9.04%

ROE

Management delivers $-1.40 in profit for every $100 of shareholder equity.

-1.40%

ROA

DURECT Corporation generates $-52.05 in profit for every $100 in assets, demonstrating efficient asset deployment.

-52.05%

Following the Money - Real Cash Generation

Operating Cash Flow

DURECT Corporation generates limited operating cash flow of $-5.31M, signaling weaker underlying cash strength.

$-5.31M

Free Cash Flow

DURECT Corporation generates weak or negative free cash flow of $-5.31M, restricting financial flexibility.

$-5.31M

FCF Per Share

Each share generates $-0.17 in free cash annually.

$-0.17

FCF Yield

DRRX converts -8.96% of its market value into free cash.

-8.96%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-9.41

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.05

vs 25 benchmark

P/B Ratio

Price to book value ratio

15.06

vs 25 benchmark

P/S Ratio

Price to sales ratio

77.23

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.44

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.98

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.40

vs 25 benchmark

ROA

Return on assets percentage

-0.52

vs 25 benchmark

ROCE

Return on capital employed

-1.51

vs 25 benchmark

How DRRX Stacks Against Its Sector Peers

MetricDRRX ValueSector AveragePerformance
P/E Ratio-9.4129.33 Better (Cheaper)
ROE-139.90%426.00% Weak
Net Margin-845.96%-11441.00% (disorted) Weak
Debt/Equity0.440.78 Strong (Low Leverage)
Current Ratio0.985.12 Weak Liquidity
ROA-52.05%-120.00% (disorted) Weak

DRRX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews DURECT Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ